Clínic Barcelona. Hospital Universitari
<< More news


March, 17 2021

The CDB evaluates a new molecular test to detect renal transplant rejection

The study, which is being conducted in the Molecular Biology CORE Laboratory using massive parallel sequencing, aims to identify signs of rejection in kidney transplant patients from a blood sample.

The blood of transplant patients may contain circulating DNA fragments derived from the transplanted organ's cells (dd-cfDNA).  Recent studies suggest that dd-cfDNA levels from the transplanted organ could be a helpful rejection biomarker in managing kidney transplant patients.

To date, rejection confirmation techniques involve performing a biopsy on the transplanted organ. Thus, implementing molecular strategies based on circulating free DNA would reduce invasive testing and improve the clinical follow-up of renal transplant patients.


Biomedical Diagnostic Center (CDB)

Villarroel, 170 · 08036 Barcelona
Tel: +34 93 227 54 64 · Fax: +34 93 227 98 75 · ·